Navigation Links
China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
Date:11/23/2007

n November 5, 2007, the Company entered into a new drug development contract with a third party. Pursuant to the contract, the Developer will transfer a drug patent to the Company, and also is responsible for obtaining the New Drug Certificate and the Drug Manufacturing Approval from the PRC Drug Administration Authority no later than July 1, 2009. In exchange, the Company will pay up to RMB12 million (approximately $1.6 million) to the Developer. Of the total $1.6 million, approximately $933,800 and $266,800 will need to be paid before December 31, 2007 and February 25, 2008, respectively, and the final payment ranging from $0 to $400,200, depending on the date of the Manufacturing Approval, needs to be paid no later than 10 days after the grant date of the Manufacturing Approval. Further, the two parties agreed that the Company will pay sales commission to the Developer based on the sales volume of the contracted new drug during a 10 year period after this drug is put into production. If the PRC Drug Administration Authority denies the application of the Drug Manufacturing, all payments made by the Company would be fully returned to the Company by the Developer.

Ms. Zhang Jian, continued, ''We believe that many of the distractions of the failed acquisition of Enshi are behind us. This has taken considerable management time and money away from our primary focus of building a strong pharmaceutical company in China. We now have the conditional conversion of $12.5 million of debt to equity, and believe that we will dramatically improve our cash position and have a one-time gain to income when we prevail in our Enshi litigation. We are happy to be working on new drug launches, which include an exciting new drug development agreement. We look forward to updating shareholder on these new products that we are working on to ensure our continued organic growth, as well as other potential accretive acquisition opportunities to increase our earnings and have a profitab
'/>"/>

SOURCE China Biopharmaceuticals Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... 25, 2015 Accelovance, a therapeutically focused contract ... "Best Contract Research Organization" at the upcoming Vaccine Industry ... This is the eighth consecutive year ... award, winning for "Best Contract Research Organization" in 2009, ... in 2013. "We,re excited to be a ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 An increase ... ingredients in all forms of food nutrients, regulatory changes ... a substantial rise in demand for natural astaxanthin over ... started to ramp up their capacities to satisfy the ... natural and synthetic source astaxanthin (used in nutraceuticals, aqua ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
(Date:3/25/2015)... Researchers at Ancon Medical Inc. have ... enable broader and less invasive screening for cancer, ... breath screen. The Minnesota-based medical device maker will ... Administration (FDA) approval process and is targeting a ... Tagging device. , Ancon Medicals nanoparticle breakthrough comes ...
Breaking Biology Technology:Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... LLC (the "Purchaser"), a wholly owned subsidiary of Biotechnology Value ... cash tender offer to purchase any and all of the ... ) ("Avigen") that BVF does not own at a price ... offer price represents a 35% premium over Avigen,s closing stock ...
... CEDAR KNOLLS, N.J., Jan. 22 ScienceFirst ... associates have joined the Cedar Knolls office.(Photo: ... http://www.newscom.com/cgi-bin/prnh/20090122/NY61733-b )Valery Sudakin, PhD, has been ... Sudakin was an investigator at GlaxoSmithKline, where ...
... Jan. 22 MichBio, the association for,Michigan,s biosciences ... compiling,the 2009 Michigan Biosciences Directory and Resource Guide, ... biosciences companies and,organizations. The directory will be included ... bi-annual publication spotlighting Michigan,biosciences news and trends. , ...
Cached Biology Technology:BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share 2BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share 3ScienceFirst Staff Expansion 2MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide 2
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... cell factor overexpressed both in brain tumor cells and ... inducing angiogenesis. The research study, published in the April ... cells and surrounding tissues and may have substantial significance ... the most lethal types of tumor, malignant gliomas. ...
... play an important role in regulating blood flow in ... assumptions underlying today's most sophisticated brain imaging techniques and ... understanding Alzheimer's disease. , In a paper to appear ... available on-line, scientists at the University of Rochester Medical ...
... the Virginia Bioinformatics Institute at Virginia Tech have ... range of microbial genome sequences. , The VBI ... recent article published in Nucleic Acids Research (Vol.34, ... the plant pathogens Phytophthora sojae and Phytophthora ramorum. ...
Cached Biology News:Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons 2Blood flow in brain takes a twist, affecting views of Alzheimer's 2Blood flow in brain takes a twist, affecting views of Alzheimer's 3Virginia Bioinformatics Institutes launches microbial database 2
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
Edited by D. Rickwood, T.C. Ford and J.T. Steensgaard (1994) Compiles core data required by researchers carrying out any centrifugal separation, whether working with cells, organelles or macromolec...
MSE ANTI CAN. CD3:FITC/RAT ANTI CD4:RPE...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure Grade DAPI is greater than or equal to 98% pure by HPLC....
Biology Products: